Papalocal
Loading…
News
← All news
Politics

All 50 States Join Trump's 'Most Favored Nation' Medicaid Drug Pricing Program

The White House says the GENEROUS Model will save $64.3 billion in Medicaid drug costs over a decade — but independent analysts question whether the math holds up.

How does this story make you feel?

Michael Vadon / Wikimedia Commons

Every state Medicaid program in the country is now enrolled — or on the verge of enrolling — in a federal initiative that promises to cap what the government pays for certain prescription drugs at the lowest price any comparable developed nation pays. President Trump announced the milestone on September 18, 2026, as the administration framed it as the culmination of a years-long push to bring American drug prices in line with the rest of the world.

The program is called the GENEROUS Model — short for GENErating cost Reductions fOr U.S. Medicaid — and it is run by the CMS Innovation Center. All 50 states, the District of Columbia, and Puerto Rico have applied to participate, according to CMS. Forty states and Puerto Rico have already signed formal agreements; the remaining states have until September 30, 2026, to do so. The model launched in January 2026 and runs for five years.

At the center of the program are voluntary agreements with 26 pharmaceutical manufacturers, which the White House says cover roughly 90 percent of the branded U.S. drug market. Under those deals, companies provide rebates to ensure Medicaid pays no more than the lowest price charged in other developed nations for hundreds of drugs — a concept known as most-favored-nation, or MFN, pricing. Drug classes covered include oncology, diabetes, and asthma treatments.

Americans should pay the same low prices for prescription drugs that other countries pay. President Trump challenged us to end the system that makes Americans pay more, and we are delivering. The GENEROUS Model will drive down Medicaid drug costs, save taxpayers billions, and expand access to lifesaving medicines for the Americans who need them most.— Robert F. Kennedy, Jr., HHS Secretary
Medicaid programs will get the best possible price for drugs, delivering better value for taxpayers and freeing up funds to give vulnerable Americans the high-quality care they deserve.— Dr. Mehmet Oz, CMS Administrator

The administration projects the program will save $64.3 billion in federal and state taxpayer dollars over the next decade. The White House's broader accounting — which folds in MFN agreements beyond Medicaid — puts total projected savings to Americans at more than $600 billion. The administration also says the same 26 companies have committed roughly $170 billion to U.S. manufacturing and research and development, and are stocking a Strategic Active Pharmaceutical Ingredients Reserve to reduce dependence on foreign supply chains.

The White House separately claims that prescription drug prices have recorded their steepest annual decline since 1963, with prices falling every month of 2026, and that a broader platform covering more than 1,000 branded and generic medicines has already delivered more than $700 million in savings. Specific examples cited include GLP-1 drugs — the class that includes popular weight-loss and diabetes medications — starting as low as $149 a month, down from over $1,000, and more than 500,000 Medicare seniors saving a combined $216 million.

GENEROUS represents a significant milestone. By reducing even a fraction of drug spending in Medicaid, GENEROUS allows states to invest more in education, infrastructure, and other ways to support Americans with Medicaid.— Abe Sutton, CMS Innovation Center Director

Independent analysts have raised questions about the scale of the projected savings. Medicaid already receives substantial discounts from drug manufacturers through existing rebate requirements, which complicates the administration's math on how much additional savings the MFN model actually generates. The administration's figures have not been independently verified.

States that have not yet signed agreements have until the end of September to do so. CMS has published a list of participating states on its website. The five-year model will be evaluated on both drug spending and quality-of-care outcomes.

Why it matters — The GENEROUS Model represents the first time all U.S. state Medicaid programs have been enrolled in a unified most-favored-nation drug pricing structure, directly affecting drug costs for tens of millions of low-income Americans — though the true size of the savings remains contested.

⚠ Not yet confirmed

  • Prescription drug prices have recorded their steepest annual decline since 1963, with prices falling every month of 2026.
  • The broader MFN platform has delivered more than $700 million in savings and covers more than 1,000 branded and generic medicines.
  • joined by several governors in the Oval Office
  • According to Forbes
  • Independent analysts have questioned the savings projections, noting Medicaid already receives substantial existing discounts.

Sources differ on Scale of projected Medicaid savings from GENEROUS Model: $64.3 billion over 10 years (cms.gov / whitehouse.gov) vs Savings likely overstated because Medicaid already receives substantial existing manufacturer discounts (forbes.com)

Reported by whitehouse.gov, thehill.com, cms.gov, forbes.com

People in this story
  • Donald Trump
    President of the United States (2017–2021; since 2025)
  • Mehmet Öz
    Turkish-American surgeon, TV host, and government official (born 1960)

Community

Be the first to comment.

Share this story
Text Email